SS-31 Peptide for Bodybuilding: Does It Work?

SS-31 is a synthetic tetrapeptide developed by Hazel Szeto and Peter Schiller at Weill Cornell in the early 2000s (Szeto, 2006). Sequence: D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2. The D-arginine resists enzymatic breakdown, and the aromatic-basic pattern gives it strong affinity for cardiolipin in the inner mitochondrial membrane. It is water-soluble, cell-permeable without a transporter, and concentrates roughly 1,000-fold in mitochondria versus cytoplasm.

The drug-development name is elamipretide. Stealth Biotherapeutics licensed it as Bendavia and ran trials in heart failure, Barth syndrome, MELAS, and primary mitochondrial myopathy. Results were mixed: EMBRACE missed its endpoint, MMPOWER-3 missed, Barth syndrome (TAZPOWER) looked more promising. As of 2026, elamipretide is not FDA-approved for any indication.

Bodybuilders picked up on SS-31 through longevity podcasts and the overlap between anti-aging and performance communities. The logic: lifters past 35 see declines in mitochondrial efficiency that cap endurance, slow recovery, and limit training volume. If SS-31 can restore some of that efficiency, it becomes interesting as a long-horizon tool.

Honest framing: SS-31 is not a muscle-building peptide. It does not raise IGF-1, suppress myostatin, or boost testosterone. For growth effects, see CJC-1295 and ipamorelin benefits. For recovery, see peptides for recovery. SS-31 lives upstream of both, at the mitochondrial level.

Cells run on ATP, and most ATP is built by the mitochondrial electron transport chain. That chain depends on cardiolipin, a phospholipid unique to the inner mitochondrial membrane. Cardiolipin anchors respiratory complexes (especially Complex IV and ATP synthase) in the right spatial arrangement. When cardiolipin oxidizes from aging, metabolic stress, or high training volume, complexes drift apart, ATP output falls, and electron leakage rises. Leaked electrons become reactive oxygen species (ROS), which damage more cardiolipin in a feed-forward loop.

SS-31 binds cardiolipin and protects it from oxidation. Isolated mitochondria studies show SS-31 cuts hydrogen peroxide by 30 to 50%, raises ATP synthesis 20 to 40%, and restores cristae morphology in damaged mitochondria (Birk et al., 2013). In aged mouse skeletal muscle, 8 weeks of SS-31 restored exercise capacity to near-young levels (Siegel et al., 2013).

Bodybuilding relevance: type I fibers and the oxidative portion of type IIa fibers depend on mitochondrial density for sustained output. If SS-31 improves that substrate, expect better endurance in high-rep sets, faster between-set recovery, and less between-session fatigue, not bigger biceps.

Mitochondrial biogenesis is a secondary, indirect effect. SS-31 does not directly activate PGC-1alpha. It reduces oxidative burden, which lets training and other stressors drive biogenesis more efficiently. Whether that translates to trained human lifters is unproven.

No human efficacy data exists for SS-31 as a bodybuilding aid. Every community protocol is extrapolated from heart failure and mitochondrial disease trials, scaled down for a healthy user. Treat this as a description of practice, not a medical recommendation.

Typical research-use protocol: - Dose: 5 to 10 mg per day, subcutaneous - Timing: morning, empty stomach, same time each day - Cycle: 4 to 8 weeks on, at least 4 weeks off - Reconstitution: 50 mg vial with 2 mL bacteriostatic water gives 25 mg/mL (0.2 to 0.4 mL per dose)

Published human trials used 4 mg/day (Barth syndrome) up to 40 mg/day (heart failure IV). The 5 to 10 mg subcutaneous range sits at the low end. For reconstitution math, use the peptide reconstitution calculator.

Injection: subcutaneous abdominal fat, rotating sides, about 2 inches from the navel. A 29- or 30-gauge insulin syringe works cleanly. See how to inject peptides.

What users report: subtle effects. Better endurance in final sets, reduced next-day soreness, improved fasted cardio recovery. The first week usually feels like nothing. Mitochondrial changes need 2 to 3 weeks to accumulate.

Storage: reconstituted SS-31 is stable 28 days at 2 to 8 degrees Celsius. Lyophilized vials keep 24 months frozen or 12 months refrigerated. Protect from light.

Animal data: fairly strong. SS-31 restores exercise capacity in aged mice to near-young levels in 8 weeks, improves mitochondrial respiration in isolated fibers, and reduces muscle fatigue in ischemia-reperfusion models. Dose-response curves are clean, mechanism is well characterized.

Human clinical data (heart failure, mitochondrial disease): mixed. EMBRACE missed endpoints. MMPOWER-3 missed its primary endpoint with some secondary signal. Barth syndrome (TAZPOWER) looked better and drove the FDA resubmission. Tolerability was good, mild injection site reactions dominated.

Human data in trained lifters: essentially zero. A 2020 study in older sedentary adults showed SS-31 improved skeletal muscle mitochondrial function and exercise tolerance versus placebo, but the cohort was not athletic (Roshanravan et al., 2020).

Community reports: mostly positive, heavily biased. People who buy 300-dollar peptides tend to feel better. Controlled before/after data is non-existent. The plausible-mechanism argument is strong; the it-definitely-works-for-lifters argument is weak.

Our position: SS-31 is reasonable for a 40-plus lifter who has already optimized training, sleep, nutrition, and core peptides (BPC-157, growth secretagogues), and accepts the experimental label. It is not a first peptide and not a shortcut to hypertrophy. For a cellular-energy peptide with more consumer data, 5-amino-1MQ is better characterized.

Across roughly 1,500 participants in human trials, SS-31 has a favorable safety profile. Most common adverse events:

• Injection site reactions (mild redness, itching, small welts): most frequent
• Headache: occasional, resolves in first week
• Mild GI upset: uncommon, more frequent at higher IV doses
• Dizziness at peak plasma levels: rare, dose-dependent
• Transient liver enzyme elevations: rare, reversible

No serious adverse events have been consistently attributed to SS-31 in published trials. Long-term human safety data does not exist.

Who should avoid SS-31: anyone under 25, pregnant or breastfeeding, active cancer or known mitochondrial disease without specialist oversight, competitive athletes subject to WADA testing (assume banned under S0), or anyone on multi-drug psychiatric or cardiovascular regimens.

Research-grade product risks: SS-31 from research vendors is not pharmaceutical-grade. Purity varies, independent HPLC testing is uncommon. Reconstitution errors, contaminated bacteriostatic water, and improper storage introduce risks separate from the peptide. See the peptide safety guide and are peptides legal.

Rotate injection sites daily, use a fresh syringe each time, clean with 70% isopropyl alcohol. Never mix SS-31 in the same syringe as other peptides. It wrecks dose accuracy and makes adverse event attribution impossible.

SS-31 is mechanistically orthogonal to most bodybuilding peptides. It does not share receptors with growth peptides, does not affect HPTA, and does not change systemic hormone levels at standard doses.

Mitochondrial + growth stack (advanced, 40+): - SS-31: 5 to 10 mg subcutaneous, morning - CJC-1295 + ipamorelin: 100 mcg + 200 mcg, pre-bed - BPC-157: 250 mcg subcutaneous, post-workout - Cycle: 8 weeks on, 4 weeks off

CJC/Ipa drives GH pulses and IGF-1 for hypertrophy. SS-31 improves the cellular substrate training acts on. BPC-157 protects connective tissue. Three layers of the adaptation problem. See CJC-1295 ipamorelin benefits and the peptide stacking guide.

Mitochondrial + metabolic stack: SS-31 5 mg subcutaneous morning, plus 5-amino-1MQ 50 to 150 mg oral morning, 6 to 8 weeks. 5-amino-1MQ inhibits NNMT and raises NAD+; SS-31 improves the mitochondria that use it. Theoretical overlap is good, empirical overlap untested. See 5-amino-1MQ dosage.

Do not stack SS-31 with MOTS-c at the same time of day (both are mitochondrial-targeted, signaling overlap is uncharacterized). Avoid high-dose NMN (above 1 g/day) during the first 2 weeks. Use the peptide stack calculator to check compatibility, and see the peptide dosage chart for reference ranges.

Order of introduction: run SS-31 solo for 2 weeks before adding other peptides so you can attribute adverse events correctly.

Cost: at 5 to 10 mg/day and roughly 200 USD per 50 mg vial, an 8-week cycle runs 600 to 1,200 USD all-in. That is 3 to 6 times a BPC-157 or CJC/Ipa cycle, for less human performance data.

Legality: SS-31/elamipretide is a research chemical in the US. Legal to purchase from research vendors when labeled "for research use only, not for human consumption." Possession for personal use is not federally criminalized. State laws and professional-license implications matter more than federal risk. See are peptides legal.

WADA/NCAA: not explicitly listed, but S0 ("non-approved substances") captures anything not approved for human therapeutic use. Treat SS-31 as banned for any tested athlete.

ROI: for most lifters under 35, 600 to 1,200 dollars on SS-31 is worse spending than coaching, a better-programmed block, or a DEXA and blood panel. For a dialed-in 45-year-old who has exhausted the fundamentals, SS-31 becomes a defensible experiment.